Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IDEXX LABORATORIES INC /DE
Report date May 10, 2018 · Filed May 11, 2018
Section 16 reporting ended · disclosed 2018-05-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,786 |
Reported balance
After 2018-05-10 transaction · row 1
1 source rowRow 1 · 2018-05-10 · Sale · Disposed 9,470 · Balance 31,786 F1: Represents the weighted average sales price of the shares sold ranging from a low of $208.13 to a high of $208.81 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average sales price of the shares sold ranging from a low of $208.13 to a high of $208.81 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2018 Filed May 11, 2018 22:59 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 9,470 | $208.36 | $1,973,162.57 |
DisclosureSEC source: 0001140361-18-023097 · doc1.xml · nonDerivative · entry 1 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,786 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $208.13 to a high of $208.81 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 22:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,000 | $184.48 | $737,938.80 |
DisclosureSEC source: 0001140361-18-009900 · doc1.xml · nonDerivative · entry 1 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,256 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $184.32 to a high of $184.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 22, 2017 Filed May 23, 2017 12:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,000 | $162.55 | $812,769.00 |
DisclosureSEC source: 0001140361-17-021820 · doc1.xml · nonDerivative · entry 1 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,256 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $162.2491 to a high of $162.9229 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:10 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,046 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001140361-17-018656 · doc1.xml · derivative · entry 2 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,046 Underlying: Common Stock · 3,046 shares Expires 2027-05-02 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on May 3, 2018. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:10 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-018656 · doc1.xml · derivative · entry 1 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,094 Underlying: Common Stock · 289 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:45 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,000 | $141.71 | $708,534.00 |
DisclosureSEC source: 0001140361-17-008415 · doc1.xml · nonDerivative · entry 1 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,256 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $141.6166 to a high of $141.8165 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 6,602 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-007452 · doc1.xml · derivative · entry 2 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,602 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,301 shares on February 14, 2012, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split").? The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 6,602 | $38.80 | $256,124.59 |
DisclosureSEC source: 0001140361-17-007452 · doc1.xml · nonDerivative · entry 1 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2016 Filed Nov 9, 2016 22:35 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,000 | $109.87 | $549,359.00 |
DisclosureSEC source: 0001140361-16-085650 · doc1.xml · nonDerivative · entry 1 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,654 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $109.60 to a high of $109.9975 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.